Please login to the form below

Not currently logged in

Targovax appoints chief financial officer

Dr Erik Digman Wiklund succeeds Oystein Soug

Targovax Dr Erik Digman WiklundTargovax has appointed Dr Erik Digman Wiklund as its new chief financial officer from April this year, succeeding Oystein Soug who became the firm's chief executive officer in November 2016.

Dr Wiklund joins the Oslo, Norway-based immuno-oncology specialist from Aker Biomarine Antarctic, where he served as director of product innovation.

He also brings experience from cancer biotech Algeta ASA, and management consulting expertise from McKinsey & Company's pharma and healthcare practice.

Soug said: “We are delighted to announce the appointment of Erik as our new chief financial officer.

“He has an impressive track record in commercial and operational roles in the biotechnology industry, combined with a strong scientific background.

“Erik's breadth of expertise will be key as we approach a number of important milestones in 2017 and 2018 within our innovative clinical pipeline, designed to help patients' own immune system to fight cancer.”

18th January 2017

From: Sales



Featured jobs

Subscribe to our email news alerts


Add my company
Four Health Media

Four Health Media creates world class integrated media solutions with global reach, deep insight, innovative methods and a highly personal...

Latest intelligence

Digital health
The untapped potential to transform healthcare...
When is it time to rebrand?
The Biosimilar Challenge